Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Elevai Labs, Inc. - Common Stock (NQ: ELAB )

0.0289 -0.0301 (-51.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Elevai Labs, Inc. - Common Stock

< Previous 1 2 Next >
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock
From Elevai Labs Inc.
Via GlobeNewswire
REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device
From Elevai Labs Inc.
Via GlobeNewswire
7 Penny Stocks to Watch Now: ELAB, RJDG, BTTC, ATCH, CBDW, and More!
Via AB Newswire
Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondrial Innovation and Elevai Exosomes™
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health Applications
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc. Subsidiary, Elevai Skincare, Announces The Elevai S-Series Hair and Scalp Care Product Line
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc. Subsidiary, Elevai Skincare to Debut Upcoming New Product Line at The Aesthetic Show 2024
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Subsidiary, Elevai Skincare, to Present at the Beauty Through Science Conference in Stockholm
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc. Reports First Quarter 2024 Financial Results
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments
From Elevai Labs Inc.
Via GlobeNewswire
ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial Results
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market
ELEVAI Physician-Dispensed Skincare Now Available Direct to Consumers 
From Elevai Labs Inc.
Via GlobeNewswire
ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office
Utility Patent Covers the formulation for ELEVAI’s flagship exosome-based skin care products 
From Elevai Labs Inc.
Via GlobeNewswire
ELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach
From Elevai Labs Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.